| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.004 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.095 | 0.004 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.092 | 0.004 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.006 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.006 |